PRODUCT
Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study
Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Philips and AWS Strengthen Strategic AI Partnership, Expanding Cloud-Enabled Diagnostics to Europe
Philips, AWS, Strategic AI Collaboration, Cloud-Enabled Diagnostics, European Expansion, Healthcare Innovation, Integrated Diagnostics Portfolio, Generative AI Applications
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence
Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges
Neurogene’s Rett Syndrome Gene Therapy Shows Efficacy but Raises Safety Concerns
Neurogene, Rett syndrome, gene therapy, NGN-401, AAV vector, clinical trial, safety concerns, efficacy results
Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti
Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma
FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks
CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.